Silencing Herpes Simplex Virus With A Vaginal Microbicide

Below is result for Silencing Herpes Simplex Virus With A Vaginal Microbicide in PDF format. You can download or read online all document for free, but please respect copyrighted ebooks. This site does not host PDF files, all document are the property of their respective owners.

doi:10.1038/nature04263 LETTERS

An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection Deborah Palliser1,2, Dipanjan Chowdhury1,2, Qing-Yin Wang3, Sandra J. Lee4, Roderick T. Bronson5, David M. Knipe3 & Judy Lieberman1,2 Herpes simplex virus 2 (HSV-2) infection causes significant morbidity1 and is an important cofactor for the transmission of

Inhibition of HIV transmission in human cervicovaginal

strategy is a topical vaginal microbicide. Sexual transmission of herpes simplex virus type 2 (HSV-2) in mice can be inhibited by intravaginal siRNA application. To overcome the challenges of knocking down gene expres-sion in immune cells susceptible to HIV infection, we used chimeric RNAs composed of an aptamer fused to

RNA interference How to kill your RNA - RSC

School, US has found that vaginal applications of siRNAs protect mice from a sexually transmitted infection lethal herpes simplex virus type 2. An siRNA used as a microbicide could protect against viral infections with a similar infection route. While siRNAs work well if delivered into tissues that are relatively easy to access, systemic

Expression And Characterization Of Antimicrobial Peptides

against glycoprotein D of the herpes simplex virus (Mayfield et al., 2003). The expression levels The expression levels of these proteins are mostly 2~20% of TSP, but could be even higher than RuBisCo (Oey et al ,

Retrovirology BioMed - CORE

Herpes simplex virus 2 (HSV-2) infection causes signifi-cant morbidity and is an important cofactor for transmis-sion of HIV infection. We investigated whether intravaginal application of siRNAs could protect mice from lethal herpes simple virus type 2 (HSV-2) vaginal infection. siRNAs mixed with lipid are efficiently taken up

Harnessing RNA interference to prevent or treat HSV-2 and HIV

Herpes simplex virus 2 (HSV-2) infection causes signifi-cant morbidity and is an important cofactor for transmis-sion of HIV infection. We investigated whether intravaginal application of siRNAs could protect mice from lethal herpes simple virus type 2 (HSV-2) vaginal infection. siRNAs mixed with lipid are efficiently taken up

Review Article Silencing Sexually Transmitted Infections

], respiratory syncytial virus [RSV] [ ], and herpes simplex virus- [ , ]), in ammatory disorders [ ], and a variety of cancers [ , ]. erapeutically relevant siRNAs can be introduced to the endogenous RNAi pathway at various stages ( Figure ). For example, siRNAs can be derived from short hairpin

Durable Knockdown and Protection From HIV Transmission in

CD4-AsiCs Durably Protect Against Vaginal HIV Transmission gene silencing increased over the rst week. !e slow onset of gene silencing by CD4-AsiCs in vitro was reproducible (data not shown). CCR5 expression was stably reduced by ~75% for 3%weeks, and then gradually increased. A#er 5 weeks of culture,

© Vilniaus universitetas, 2007 RNA interference: from a

the silencing of transposon elements, repetitive genes and vi-ruses, processes that are crucial for maintaining the genome stability (17 19). While progress is being made in understand-ing RNAi, a very important class of short RNAs, named micro-RNAs, has been discovered (20, 21). MicroRNAs are abundant

Expression and characterization of antimicrobial peptides

herpes simplex virus (Mayfield et al., 2003). The expres-sion levels of these proteins are mostly 2% 20% of total soluble protein (TSP) but could be even higher than RuBi-sCo (Oey et al., 2009; Ruhlman et al., 2010). Other advantages of chloroplast transformation include multi-gene engineering, transgene containment, lack of position

Cell Host & Microbe Article

Genital Herpes Simplex Virus 2 (HSV-2) infection causes signifi-cant morbidity (Whitley, 2001) and is an important cofactor for HIV-1 infection (Wald and Link, 2002; Serwadda et al., 2003; Corey et al., 2004). A vaginal microbicide able to protect against HSV-2 transmission could contribute significantly to controlling sexually transmitted

Silencing Viral Infection

as a microbicide or for other antiviral prevention or treatment indications; and on cell-type-specifi c small interfering RNA delivery using an antibody fragment protamine fusion protein. Citation: Dykxhoorn DM, Lieberman J (2006) Silencing viral infection. PLoS Med 3(7): e242. DOI: 10.1371/journal.pmed.0030242 DOI: 10.1371/journal.pmed.0030242